ArticleJournal of inflammation research2026
A New Perspective on Predicting PLA2R-Associated Membranous Nephropathy Relapse: The Value of a Genetic Risk Score.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Animal models of idiopathic membranous nephropathy: Recent advances and future perspectives.Animal models and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Membranous nephropathy (MN) is a common glomerular disease characterized by high relapse rates and heterogeneous outcomes. This study aimed to develop a genetic risk score (GRS) based on five MN-associated single nucleotide polymorphisms (SNPs) and assess its predictive value for disease relapse. Methods: In this prospective study, we analyzed data from 234 patients with phospholipase A2 receptor (PLA2R)-associated MN between January 2020 and December 2023. Genotyping for five SNPs associated with MN risk (rs28383345, rs2187668, rs35771982, rs3749117, and rs4664308) was performed. A GRS was constructed and Cox regression models were used to assess risk factors for remission and relapse. Predictive performance was evaluated using Cox regression, time-dependent receiver operating characteristic (tROC) curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), Akaike information criterion (AIC), Bayesian information criterion (BIC), likelihood ratio test (LRT), and cross-validation. Results: Over a median follow-up duration of 28.0 (IQR 20.0, 39.0) months, the cumulative remission rate was 85.5%, with 47% relapsing. A high GRS was significantly associated with the risk of relapse (HR = 1.885, 95% CI: 1.331-2.585; P < 0.001). Adding GRS to the base model consistently increased the time-dependent AUC at years 2, 4, and 5 (all P < 0.05). Notably, assessments using risk reclassification metrics (IDI/NRI) and model fit metrics (LRT/AIC/BIC) also verified significant improvements in model performance across multiple years. Critically, rigorous repeated cross-validation demonstrated that the overall C-index gain provided by the GRS was both stable and significant (P < 0.05), and further year-by-year cross-validation confirmed that this advantage persisted across all evaluated years (all P < 0.05). Furthermore, sensitivity analysis further confirmed the robustness of the GRS. Conclusion: This study is the first to apply a GRS in predicting relapse in PLA2R-associated MN. GRS significantly enhances predictive accuracy, offering a valuable tool for personalized risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.